Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition

Molecular Analysis of Plasma From Patients With ROS1-Positive NSCLC

(2019) Ibiayi Dagogo-Jack et al.   Journal of Thoracic Oncology

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001

(2019) A T Shaw et al.   ANNALS OF ONCOLOGY

The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models

(2019) Ryohei Katayama et al.   Nature Communications

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials

(2019) Alexander Drilon et al.   LANCET ONCOLOGY

Resistance Mechanisms to Targeted Therapies inROS1+andALK+Non–small Cell Lung Cancer

(2018) Caroline E. McCoach et al.   CLINICAL CANCER RESEARCH

Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing

(2018) Rahul Nahar et al.   Nature Communications

Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion.

(2018) Zofia Piotrowska et al.   Cancer Discovery

EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes

(2018) Nicolas Marcoux et al.   JOURNAL OF CLINICAL ONCOLOGY

Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas

(2017) June-Koo Lee et al.   JOURNAL OF CLINICAL ONCOLOGY

Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer Harboring ROS1 Rearrangement

(2017) Sun Min Lim et al.   JOURNAL OF CLINICAL ONCOLOGY

Recent Advances in Targeting ROS1 in Lung Cancer

(2017) Jessica J. Lin et al.   Journal of Thoracic Oncology

Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial

(2017) Alice T Shaw et al.   LANCET ONCOLOGY

Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?

(2017) Sai-Hong Ignatius Ou et al.   LUNG CANCER

Tracking the Evolution of Non–Small-Cell Lung Cancer

(2017) Mariam Jamal-Hanjani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Patients harboring ALK rearrangement adenocarcinoma after acquired resistance to crizotinib and transformation to small-cell lung cancer: a case report

(2017) You-cai Zhu et al.   OncoTargets and Therapy

Transformation ofALKrearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib

(2016) N. Takegawa et al.   ANNALS OF ONCOLOGY

A Case of ALK- Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib

(2016) Yoon Jin Cha et al.   Journal of Thoracic Oncology

Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib

(2016) Shiro Fujita et al.   Journal of Thoracic Oncology

Histological transformation of ALK rearranged adenocarcinoma into small cell lung cancer: A new mechanism of resistance to ALK inhibitors

(2016) Delphine Levacq et al.   LUNG CANCER

Analysis of protein-coding genetic variation in 60,706 humans

(2016) Monkol Lek et al.   NATURE

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F

(2016) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer

(2015) A. Drilon et al.   CLINICAL CANCER RESEARCH

Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin

(2015) Matthew G Oser et al.   LANCET ONCOLOGY

Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion-Positive Cancer

(2014) R. Katayama et al.   CLINICAL CANCER RESEARCH

Anchored multiplex PCR for targeted next-generation sequencing

(2014) Zongli Zheng et al.   NATURE MEDICINE

Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

(2014) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Patient-derived models of acquired resistance can identify effective drug combinations for cancer

(2014) Adam S. Crystal et al.   SCIENCE

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

(2013) H. A. Yu et al.   CLINICAL CANCER RESEARCH

Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1

(2013) Mark M. Awad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer

(2013) Kurtis D. Davies et al.   PLoS One

ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

(2012) Kristin Bergethon et al.   JOURNAL OF CLINICAL ONCOLOGY

RET, ROS1 and ALK fusions in lung cancer

(2012) Kengo Takeuchi et al.   NATURE MEDICINE

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine